This is a Humira news story, published by Yahoo Finance, that relates primarily to Skyrizi news.
For more Humira news, you can click here:
more Humira newsFor more Skyrizi news, you can click here:
more Skyrizi newsFor more drug discoveries news, you can click here:
more drug discoveries newsFor more news from Yahoo Finance, you can click here:
more news from Yahoo FinanceOtherweb, Inc is a public benefit corporation, dedicated to improving the quality of news people consume. We are non-partisan, junk-free, and ad-free. We use artificial intelligence (AI) to remove junk from your news feed, and allow you to select the best health news, business news, entertainment news, and much more. If you like drug discoveries news, you might also like this article about
Oncology product sales. We are dedicated to bringing you the highest-quality news, junk-free and ad-free, about your favorite topics. Please come every day to read the latest Humira revenues news, Neuroscience revenues news, drug discoveries news, and other high-quality news about any topic that interests you. We are working hard to create the best news aggregator on the web, and to put you in control of your news feed - whether you choose to read the latest news through our website, our news app, or our daily newsletter - all free!
Imbruvica revenuesBenzinga
•65% Informative
Revenues reached $14.46 billion , up 4.3% on a reported basis or 3.5% on an operational basis.
Humira revenues were $2.81 billion (down 29.8% ) Skyrizi sales reached $273 billion (up 44.8% ), and Rinvoq revenues were up 55.8% .
AbbVie announced it is discontinuing further development of the experimental Alzheimer’s drug ABBV-916.
VR Score
52
Informative language
46
Neutral language
52
Article tone
formal
Language
English
Language complexity
40
Offensive language
not offensive
Hate speech
not hateful
Attention-grabbing headline
detected
Known propaganda techniques
not detected
Time-value
medium-lived
External references
7
Source diversity
2
Affiliate links
no affiliate links